申请人:Lipha, Lyonnaise Industrielle Pharmaceutique
公开号:US05001134A1
公开(公告)日:1991-03-19
The present invention relates to piperidines denoted by the formula: ##STR1## in which X is the 4-fluorobenzoyl, 2-(4-fluorophenyl)-1,3-dioxolan-2-yl or 6-fluoro-1,2-benzisoxazol-3-yl group, Y is a hydrogen atom or the hydroxyl group, m is an integer between 0 and 4 inclusive, n is 0 or 1, Q is a nitrogen atom or the methine group; when Q is a nitrogen atom, R is the cyano group or the carbamoyl group; when Q is the methine group, R is the nitro group; R.sup.1 and R.sup.2 may be identical or different and are hydrogen, a lower alkyl radical, the phenyl radical, the 2,2,2-trifluoroethyl group or the 2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl group; or the NR.sup.1 R.sup.2 structural unit is the piperidino radical or the 4-(4-fluorobenzoyl)-1-piperidinyl group. Application of these compounds as antihypertensive medications.
本发明涉及具有以下通式的哌啶类化合物:##STR1## 其中,X为4-氟苯甲酰基、2-(4-氟苯基)-1,3-二氧戊环-2-基或6-氟-1,2-苯并异噁唑-3-基团;Y为氢原子或羟基;m为0至4的整数(含0和4);n为0或1;Q为氮原子或甲川基;当Q为氮原子时,R为氰基或氨基甲酰基;当Q为甲川基时,R为硝基;R1和R2可以相同或不同,为氢、低级烷基、苯基、2,2,2-三氟乙基或2-[4-(4-氟苯甲酰基)-1-哌啶基]乙基;或者NR1R2结构单元为哌啶子基或4-(4-氟苯甲酰基)-1-哌啶基。这些化合物用作抗高血压药物的应用。